VSTMVerastem, Inc.
- Analyst Upgrades
Mizuho Maintains Outperform on Verastem, Raises Price Target to $14
Mizuho analyst Graig Suvannavejh maintains Verastem with a Outperform and raises the price target from $13 to $14. ...
- Analyst Upgrades
Jefferies Maintains Buy on Verastem, Raises Price Target to $13
Jefferies analyst Faisal Khurshid maintains Verastem with a Buy and raises the price target from $11 to $13. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19
RBC Capital analyst Leonid Timashev maintains Verastem with a Outperform and raises the price target from $14 to $19. ...
- Analyst Upgrades
BTIG Maintains Buy on Verastem, Raises Price Target to $24
BTIG analyst Jeet Mukherjee maintains Verastem with a Buy and raises the price target from $18 to $24. ...
- Earnings Call Transcripts
Verastem Oncology VS-7375 R&D Update - VERASTEM INC
Good morning, everyone. For those that don't know me, I'm Julissa Vianna, the Senior Vice President of Corporate Communications, Investor Relations, and Patient Advocacy. We're really excited to have you here today, and ...
- BusinessWire
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today ...
- BusinessWire
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
Accomplished biopharmaceutical executive Michael P. Bailey appointed President and CEO to advance Verastem’s commercial business and lead pipeline asset advancement for VS-7375, a potential best-in-class ...
- BusinessWire
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a majority of ...
- Analyst Upgrades
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem with a Buy and maintains $18 price target. ...
- BusinessWire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem with a Buy and maintains $18 price target. ...
- Analyst Upgrades
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem with a Buy and maintains $18 price target. ...
- BusinessWire
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with KRAS/NRAS/BRAF triple ...
- BusinessWire
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
RAMP 201 study supported FDA Accelerated Approval of AVMAPKI FAKZYNJA CO-PACK for treatment of KRAS-mutated recurrent LGSOC following prior systemic therapy Across patients with KRAS wild-type and KRAS-mutated ...
- PR Newswire
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the... ...
- BusinessWire
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Oral presentation of the results from the RAMP 201J study of avutometinib plus defactinib in recurrent LGSOC in Japanese patients New external control arm analysis of avutometinib plus defactinib versus ...
- Analyst Upgrades
Wolfe Research Initiates Coverage On Verastem with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Verastem with a Outperform rating. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem with a Buy and maintains $18 price target. ...
- Analyst Upgrades
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem with a Buy and maintains $18 price target. ...
- BusinessWire
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
- BusinessWire
Verastem Oncology to Participate in Upcoming September Investor Conferences
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate ...
- Analyst Upgrades
Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13
Mizuho analyst Graig Suvannavejh maintains Verastem with a Outperform and lowers the price target from $14 to $13. ...
- Analyst Upgrades
Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
Guggenheim analyst Michael Schmidt maintains Verastem with a Buy and lowers the price target from $14 to $12. ...
- BusinessWire
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ ...
- BusinessWire
Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
TARGET-D 203 trial to evaluate VS-7375 both as monotherapy and in combination with cetuximab or panitumumab in previously treated metastatic colorectal cancer A cohort in TARGET-D 203 will also evaluate the ...